glp-1 stomach paralysis is the rare Ozempic risk worth watching GLP-1 Gastroparesis: Hidden Dangers Beyond

To view or add a comment, sign in An interesting prespecified analysis from the FOURIER trial, highlighting how obesity is not only a cardiovascular risk factor but also a modifier of therapeutic benefit

J Neurosci (2011) 31:390413

[7] [26] The FDA has approved these agents for glycemic control in type 2 diabetes based on their demonstrated efficacy in lowering hemoglobin A1c levels by approximately 0.51.5%, depending on the specific agent and dose

Experiment to find what works for your body

This has been observed following vildagliptin treatment using both the hyperinsulinemic-euglycemic clamp test and indirect measures of insulin sensitivity (50, 57)